

ATTORNEY DOCKET NO. 21101.0034U3
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Janette C. Roberts)	
)	Group Art Unit: 1623
Serial No. 10/051,463)	
)	
Filed: January 18, 2002)	Examiner: Peselev, Ellie
)	
For: PRODRUGS AND CONJUGATES OF)	Confirmation No. 2964
THIOL- AND SELENOL-CONTAINING)	
COMPOUNDS AND METHODS OF USE)	
THEREOF)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

04/12/2004 HVUONG1 00000036 10051463

April 5, 2004

01 FC:1806 180.00 OP

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO 1449 is a listing of documents known to Applicants and/or their attorneys. A copy of each of these documents is enclosed.


This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(c), in that neither a final Office Action nor a Notice of Allowance has been mailed to Applicants. Therefore, consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

**ATTORNEY DOCKET NO. 21101.0034U3
SERIAL NO. 10/051,463**

A Credit Card Payment Form PTO-2038 authorizing payment in the amount of \$290.00 (\$55.00 for the Terminal Disclaimer Fee, \$55.00 for the extension of time fee, and \$180.00 for the Information Disclosure Statement) is enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.


Lawrence A. Villanueva
Registration No. 43,968


NEEDLE & ROSENBERG, P.C.
Customer Number 23859
678/429-9300 (Phone)
678/420-9301 (Fax)

CERTIFICATE OF MAILING UNDER 1.8

I hereby certify that this document and any documents referenced herein as being enclosed herein is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 23313-1450, on the date indicated below.


Lawrence A. Villanueva

04/05/04
Date



Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**LIST OF INFORMATION CITED BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/051,463
Filing Date	Jan. 18, 2002
First Named Inventor	Jeanette C. Roberts
Group Art Unit	1623
Examiner Name	E. Peslev

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	B1	Baruchel et al. "In vivo Selective Modulation of Tissue Glutathione in a Rat Mammary Carcinoma Model" <i>Biochem. Pharmacol.</i> 50(9):1505-1508, 1995
	B2	Bezlepkin et al. "The Prolongation of Survival in Mice by Dietary Antioxidants Depends on their Age by the Start of Feeding this Diet" <i>Mechanisms of Ageing and Development</i> 92:227-234, 1996
	B3	Bohm et al. "A Feasibility Study of Cisplatin Administration with Low-Volume Hydration and Glutathione Protecting in the Treatment of Ovarian Carcinoma" <i>Anticancer Res</i> 11:1613-1616, 1991
	B4	Cai et al. "Biochemical and Morphological Changes in the Lenses of Selenium and/or Vitamin E Deficient Rats" <i>Biomed. And Environ. Sci.</i> 7:109-115, 1994
	B5	Clark et al. "Effects of Selenium Supplementation for Cancer Prevention in Patients with Carcinoma of the Skin" <i>JAMA</i> 276(24):1957-1963, December 25, 1996
	B6	Crary et al. "Potential Clinical Applications for High-Dose Nutritional Antioxidants" <i>Medical Hypotheses</i> 13:77-98, 1984
	B7	Dorr, Robert "Chemoprotectants for Cancer Chemotherapy" <i>Seminars in Oncology</i> Vol. 18, No. 1, Suppl 2, pp 48-58, February 1991
	B8	El-Bayoumy et al. "Chemoprevention of Cancer by Organoselenium Compounds" <i>J. Cell. Biochem. Supplement</i> 22:92-100, 1995
	B9	Konstantinov et al. "Antitumor, Nephrotoxic and Clastogenic Effect of cis-DDP with DDTC or NAC" <i>Neoplasma</i> 41(5):253-258, 1994
	B10	Kumar et al. "Radioprotection by Antioxidant Enzymes and Enzyme Mimetics" <i>Pharmac. Ther.</i> 39:309-309, 1988
	B11	Lautermann et al. "Glutathione Protection against Gentamicin Ototoxicity Depends on Nutritional Status" <i>Hearing Research</i> 86:15-24, 1995
	B12	Nagasawa et al. "Prodrugs of L-Cysteine as Liver-Protective Agents, 2(RS)-Methylthiazolidine4R-Carboxylic Acid, a Latent Cysteine" <i>J. Med. Chem.</i> 25(5):489-491, May 1982
	B13	Steare, SE and Yellon, DM "The Potential for Endogenous Myocardial Antioxidants to Protect the Myocardium Against Ischaemia-Reperfusion Injury: Refreshing the Parts Exogenous Antioxidants Cannot Reach?" <i>J. Mol. Cell. Cardiol.</i> 27:65-74, 1995
	B14	M. Tamba "Role of Thiols in Radioprotection: Radiation Chemical Aspects" <i>J Biosci.</i> 44c:857-862, 1989
	B15	Waters et al. "Antimutagenicity Profiles for Some Model Compounds" <i>Mutation Res.</i> 238:57-85, 1990

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.